Anivive Lifesciences

About Anivive Lifesciences

Anivive Lifesciences is a pet pharmaceutical company focused on transforming pet health through innovative technology and research. Their mission is to provide lasting hope to families by developing treatments, vaccines, and novel applications to address unmet medical needs in pets.

Products & Services

Valley Fever Vaccine:A novel vaccine in development to prevent Valley Fever (Coccidioidomycosis) in dogs, currently unpreventable and spreading.

FIP Treatment:A treatment for Feline Infectious Peritonitis (FIP) aimed at extending the life expectancy of affected cats, which is typically only one week.

SearchLight DNA:A next-generation tumor genotyping tool for precision cancer treatment in pets, enabling personalized treatment plans.

Specialty Pathology:Best-in-class pathology services for veterinary oncology, powered by innovative technology and led by field experts.

AI Imaging for Fungal Diagnosis:An imaging module using deep convolutional neural networks to detect systemic fungal infections like Valley Fever in dogs.

Carbon DNA Kit:A tool providing DNA insights to identify health predispositions in pets, offering actionable advice for pet owners.

Clinical Trials Marketplace:A platform to match pets to clinical trials based on medical needs, enhancing access to studies and speeding enrollment.

Therapeutics Pipeline:Includes treatments for cancer care (e.g., Hemangiosarcoma, Osteosarcoma), fungal diseases (e.g., Blastomycosis), viral infections (e.g., FIP), and other conditions like Gingivitis for dogs and cats, all in development.

Specialties

Veterinary Oncology Fungal Disease Treatments Viral Infection Treatments AI-Powered Drug Development Precision Medicine for Pets DNA Genotyping for Pets Clinical Trial Platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Capital T: - FT: Venture Capital	A: 20000000 MR: - FA: $20 Million FAN: 20000000	D: 2025-01-27 FD: 2025-01-27	1 investors
2	RT: Donation T: - FT: Donation	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2023-03-02 FD: 2023-03-02	1 investors

Venture Capital Latest

2025-01-27

$20.0M

1 investor (Pro only)

Donation 2023-03-02

$1.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dylan Balsz

Founder and Chief Executive Officer

D

Dave Bruyette DVM

Chief Medical Officer

C

Cody Arbuckle PhD

Chief Technology Officer

C

Chad Dodd DVM

Chief Commercial Officer

E

Edward Robb DVM

Chief Strategy Officer

S

Steve Sutherland DVM

Chief Regulatory Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News